These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Activities of ciprofloxacin and sparfloxacin against Streptococcus pneumoniae. Dalhoff A Drugs; 1995; 49 Suppl 2():194-6. PubMed ID: 8549301 [No Abstract] [Full Text] [Related]
46. Management of macrolide-resistant Mycoplasma pneumoniae infection. Saegeman V; Proesmans M; Dumke R Pediatr Infect Dis J; 2012 Nov; 31(11):1210-1. PubMed ID: 22668803 [No Abstract] [Full Text] [Related]
47. Comparative in vitro activity of BAY Y 3118 with other fluoroquinolones. Molinari G; Schito GC Drugs; 1995; 49 Suppl 2():222-5. PubMed ID: 8549310 [No Abstract] [Full Text] [Related]
48. In vitro activity of sparfloxacin and other antimicrobial agents against genital pathogens. Lefèvre JC; Bauriaud R; Gaubert E; Escaffre MC; Lareng MB Chemotherapy; 1992; 38(5):303-7. PubMed ID: 1337506 [TBL] [Abstract][Full Text] [Related]
49. Two new fluoroquinolones. Med Lett Drugs Ther; 1992 Jun; 34(872):58-60. PubMed ID: 1317502 [No Abstract] [Full Text] [Related]
50. Resistance of Mycoplasma pneumoniae to erythromycin: a clinical case with severe pulmonary, cerebral and systemic complications. Clara F; Von Busch C; Goeddertz P; Novotna I J Chemother; 1989 Jul; 1(4 Suppl):411-3. PubMed ID: 16312462 [No Abstract] [Full Text] [Related]
51. Sparfloxacin, a new generation fluoroquinolone against S. pneumoniae respiratory infections. Niki Y; Tamada S; Nakabayashi M; Soejima R Drugs; 1995; 49 Suppl 2():420-2. PubMed ID: 8549385 [No Abstract] [Full Text] [Related]
52. Activity of new 4-quinolones in combination with erythromycin or tetracycline against S. pneumoniae. Morrissey I; Smith JT Drugs; 1995; 49 Suppl 2():226-7. PubMed ID: 8549311 [No Abstract] [Full Text] [Related]
53. [Analysis on antibacterial activity of common antibiotics to Mycoplasma pneumoniae]. Xin DL; Chen XG; Han X Zhonghua Er Ke Za Zhi; 2009 Apr; 47(4):305-6. PubMed ID: 19555573 [No Abstract] [Full Text] [Related]
54. Induction of resistance of Streptococcus pneumoniae to quinolones in vitro. Lafredo SC; Foleno BD; Fu KP Chemotherapy; 1993; 39(1):36-9. PubMed ID: 8383031 [TBL] [Abstract][Full Text] [Related]
55. New generations of quinolones: with particular attention to levofloxacin. Ambrose PG; Owens RC; Quintiliani R; Nightingale CH Conn Med; 1997 May; 61(5):269-72. PubMed ID: 9197076 [No Abstract] [Full Text] [Related]
56. [Efficacy of lomefloxacin in treatment of nonspecific inflammatory diseases and in prophylaxis of postoperative complications in urology]. Derevianko II; Khodyreva LA; Avdoshin VL; Andriukhin MI; Gabliia MIu Antibiot Khimioter; 1998; 43(10):36-41. PubMed ID: 9825109 [TBL] [Abstract][Full Text] [Related]
57. Comparative in vitro activity of BAY Y 3118 against selected species. Verbist L; Verhaegen J Drugs; 1995; 49 Suppl 2():264-5. PubMed ID: 8549326 [No Abstract] [Full Text] [Related]